Axsome Therapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AXSM Nasdaq 2834 www.axsome.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Axsome Therapeutics, Inc.

The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight - Aug 6th, 2026 8:31 am
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Aug 6th, 2026 8:00 am
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Aug 6th, 2026 7:50 am
Countdown to Axsome (AXSM) Q2 Earnings: Wall Street Forecasts for Key Metrics - Aug 5th, 2026 7:15 am
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates - Aug 4th, 2026 3:15 pm
Prediction: These 2 Stocks Will Keep Winning No Matter What the Market Does - Aug 4th, 2026 1:20 pm
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Aug 3rd, 2026 8:00 am
New Strong Sell Stocks for July 29th - Jul 29th, 2026 3:29 am
Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug - Jul 24th, 2026 8:06 am
Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls - Jul 21st, 2026 7:40 am
Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap? - Jul 18th, 2026 1:11 am
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance - Jul 16th, 2026 9:58 am
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy - Jul 15th, 2026 5:00 am
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 - Jul 14th, 2026 5:00 am
3 Under-the-Radar Stocks to Buy and Hold - Jul 10th, 2026 12:50 pm
Axsome Therapeutics (AXSM) Stock Looks Pricey On Sales Yet Fair On Value - Jul 9th, 2026 8:11 pm
How Investors May Respond To Axsome Therapeutics (AXSM) Advancing Solriamfetol Into Phase 3 Pediatric ADHD Trials - Jul 9th, 2026 3:14 pm
Axsome Therapeutics (AXSM) Following FOCUS 2 Dosing Is The ADHD Upside Already Priced In - Jul 9th, 2026 2:14 pm
Dow Jones Futures: Nasdaq Eyes Key Levels Amid Iran News; Nvidia, Valero, Dell, SpaceX In Focus - Jul 9th, 2026 6:09 am
Better Growth Buy: Axsome vs Revolution Medicines - Jul 9th, 2026 2:15 am